High feasibility and safety of office-based transurethral laser ablation for recurrent non-muscle invasive bladder cancer: a single-center experience
Frontiers in Oncology · 20.04.2026 · 16
DOI: 10.3389/fonc.2026.1683009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.04.2026. Verfasst von Zoran Zimak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate the feasibility, safety, and early oncological outcomes of office-based transurethral laser ablation (TULA) for recurrent non-muscle invasive bladder cancer (NMIBC).
Methods
We retrospectively reviewed 53 patients undergoing their first TULA for recurrent NMIBC at the University Hospital Centre Zagreb from March 2024 to February 2025. Inclusion criteria comprised histologically confirmed NMIBC recurrence suitable for outpatient laser ablation. Exclusion criteria included carcinoma in situ , muscle-invasive disease, prior intravesical therapy, or tumors >3 cm. Procedures were performed under local anesthesia using a holmium-YAG laser. Clinical, procedural, and oncological outcomes were analyzed, with predictors of recurrence assessed via multivariate logistic regression.
Results
The median patient age was 68 years, and 54.7% were male. Most tumors were pTa (94.3%) and low-grade (92.5%); 90.6% measured <1 cm. TULA was completed successfully in 94.3% of cases, with minimal peri-procedural complications (1.9%). At 3 months, the recurrence rate was 38.8%. Univariate analysis linked recurrence with older age, higher Charlson Comorbidity Index, and male gender. In multivariate analysis, male gender remained the only independent predictor (aOR 4.29; p=0.034). No patient progressed to muscle-invasive disease.
Conclusions
Office-based TULA is a highly feasible, safe, and cost-effective alternative for selected patients with small recurrent low-grade NMIBC, offering significant procedural and economic advantages over transurethral resection. Although early recurrence rates are notable in this high-risk cohort, oncological safety appears acceptable. Male gender may predict early recurrence, warranting further investigation in larger prospective studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia.
- Sveuciliste u Zagrebu Medicinski fakultet, Zagreb, Croatia.
- Hrvatska akademija znanosti i umjetnosti, Zagreb, Croatia.
Zitieren
APA
Zimak, Z., Vidovic, D., Kulis, T., Hauptman, D., Hudolin, T., Bakula, M., & Kastelan, Z. (2026). High feasibility and safety of office-based transurethral laser ablation for recurrent non-muscle invasive bladder cancer: a single-center experience. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1683009
Vancouver
Zimak Z, Vidovic D, Kulis T, Hauptman D, Hudolin T, Bakula M, et al. High feasibility and safety of office-based transurethral laser ablation for recurrent non-muscle invasive bladder cancer: a single-center experience. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1683009
BibTeX
@article{Zimak2026,
author = {Zimak, Zoran and Vidovic, Dominic and Kulis, Tomislav and Hauptman, Dinko and Hudolin, Tvrtko and Bakula, Mirko and Kastelan, Zeljko},
title = {High feasibility and safety of office-based transurethral laser ablation for recurrent non-muscle invasive bladder cancer: a single-center experience},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1683009}
}
EUVIMED